New capabilities continue to improve home dialysis platform success

New capabilities continue to improve home dialysis platform success

Adds Live Video and In-app Calling Capabilities to Nx2me Connected Health® Platform

NxStage has released version 2.6 of its home hemodialysis (HHD) connected health platform, Nx2me™, with the goal of providing even better support to patients on HHD. Designed to facilitate the patient’s connection to clinicians, the platform allows patients to receive the care they need during treatment whether in the comfort of their own home or on the road. This latest update to Nx2me gives patients the option to call technical support directly from the iPad app and supports live video calls so that patients can talk to a nurse face-to-face.

Hemodialysis Support When You Need It
Through live virtual sessions with a home training nurse, a patient can show the nurse what they’re seeing. When a patient has a problem or concern, the enhanced ability for virtual interaction provided by live video may help resolve issues faster and easier, reducing the burden on patients and healthcare workers.

“By enhancing our connected health platform, we are improving the patient experience and quality of care we can deliver,” said Joe Turk, President of the Renal Therapies Group at Fresenius Medical Care North America. “We’re striving to simplify the entire NxStage experience so that patients can realize the benefits of home hemodialysis feeling safe and confident with the level of support they receive.”

Simplifying Home Dialysis Through Technology
The potential for home dialysis to become more commonplace and even easier to use is heavily influenced by innovative technology of home dialysis systems.  Therefore, any advancement of connected health, as it relates to home dialysis, is a crucial step toward improving kidney care.

Nx2me is designed to simplify patient use and connect them with their clinician more effectively. In addition to providing live video and in-app calling support, the Nx2me app allows patients to record flowsheet data electronically, while the system automatically records data coming from the machine during each treatment such as rates, volumes, and pressures. The app prompts the patient or caregiver to take vitals, provides customized education, and includes 24/7 customer support. Finally, patients have access to a note-taking feature on the app to record their experiences with texts and pictures. The data is then sent to the clinician portal through which the care team can monitor and address potential issues. 

Nx2me delivers quantifiable benefits such as enhanced HHD therapy retention1. It has been associated with a 29% lower therapy discontinuation rate, excluding death and transplant, compared to HHD patients not using Nx2me1. In addition, Nx2me has been associated with a 27% improvement in HHD training graduation rates compared to HHD patients not using Nx2me1.

Source: 1. Weinhandl ED, et al. Hemodial Int. 2018 Jul;22(3):318-327. doi: 10.1111/hdi.12621.